Escitalopram oxalate

Modify Date: 2024-01-02 12:17:20

Escitalopram oxalate Structure
Escitalopram oxalate structure
 Common Name Escitalopram oxalate
CAS Number 219861-08-2 Molecular Weight 414.427
Density N/A Boiling Point 428.3ºC at 760 mmHg
Molecular Formula C22H23FN2O5 Melting Point 152-153ºC
MSDS Chinese USA Flash Point 212.8ºC

 Use of Escitalopram oxalate


Escitalopram is a selective serotonin reuptake inhibitor (SSRI) with Ki of 0.89 nM.Target: SSRIsEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.

 Names

Name Escitalopram oxalate
Synonym More Synonyms

 Escitalopram oxalate Biological Activity

Description Escitalopram is a selective serotonin reuptake inhibitor (SSRI) with Ki of 0.89 nM.Target: SSRIsEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.
Related Catalog
References

[1]. Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53(16): p. 6112-21.

[2]. Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10(1): p. 121-8.

 Chemical & Physical Properties

Boiling Point 428.3ºC at 760 mmHg
Melting Point 152-153ºC
Molecular Formula C22H23FN2O5
Molecular Weight 414.427
Flash Point 212.8ºC
Exact Mass 414.159088
PSA 110.86000
LogP 2.96858
Storage condition -20°C Freezer, Under Inert Atmosphere

 Safety Information

Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases 26-36
RIDADR NONH for all modes of transport

 Articles6

More Articles
The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats.

Pharmacol. Rep. 67 , 1183-7, (2015)

Several clinical reports have suggested that augmentation of atypical antipsychotics' activity by antidepressants may efficiently improve the treatment of negative and some cognitive symptoms of schiz...
Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors.

Neuropharmacology 84 , 46-51, (2014)

Metabotropic glutamate 5 (mGlu5) receptors are functionally connected with NMDA receptors. The antidepressant activity of the NMDA receptor antagonist ketamine in both preclinical and clinical studies...
Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats.

Neuropharmacology 97 , 251-8, (2015)

Depression during pregnancy has been linked to in utero stress and is associated with long-lasting symptoms in offspring, including anxiety, helplessness, attentional deficits, and social withdrawal. ...

 Synonyms

Lexapro (TN)
MFCD06407826
Lu-26-054-0
(1S)-1-[3-(diméthylamino)propyl]-1-(4-fluorophényl)-1,3-dihydro-2-benzofurane-5-carbonitrile oxalate
Ethandisäure--(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorphenyl)-1,3-dihydro-2-benzofuran-5-carbonitril(1:1)
ESCIFALOPRAMOXALATE
(S)-Citalopram Oxalate
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile ethanedioate
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile ethanedioate (1:1)
Escitalopram oxalate (USAN)
Lexapro
escitalopram oxalic acid
Escitalopram Oxalate
Cipralex
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile oxalate
5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (1S)-, ethanedioate (1:1)
(S)-Escitalopram Oxalate
Citalopram Impurity 2
Escitalopram (oxalate)
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Escitalopram oxalate suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Escitalopram oxalate price

Related Compounds: More...
Escitalopram-d6 oxalate
1217733-09-9
Escitalopram Impurity
91283-87-3
Escitalopram
128196-01-0
[(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-yl]-(4-fluorophenyl)methanone,oxalic acid
1217846-85-9
ethanolammonium oxalate
2799-19-1
Uranyl oxalate trihydrate
22429-50-1
Garryfoline,oxalate
63938-49-8
Barium oxalate monohydrate.
13463-22-4
Scandium(III) Carbonate Hydrate
17926-77-1
Chemsrc provides Escitalopram oxalate(CAS#:219861-08-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Escitalopram oxalate are included as well.>> amp version: Escitalopram oxalate

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved